To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment
This is a trial of prospective collection of serial blood samples after administration of COVID-19 vaccine in patients with cancer who are receiving active cancer treatment, planned to start therapy with 14 days of consent, or have had stem cell transplant. Cancer treatments and administration of vaccine are not controlled by the study.
Checked against the public recordLast updated Apr 4, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Kansas Medical Center
- Interventions being studied
- Biological: COVID-19 Vaccine
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Males and females age ≥ 18 years * Patients with breast cancer, lung cancer, malignant melanoma or who have undergone stem cell transplant or chimeric antigen receptor (CAR) T cell therapy for a hematologic malignancy. Other cancer types including hematologic malignancies may be allowed if they are receiving treatments outlined in section 4.1.4 * Solid Tumor patients and those with hematologic malignancies: Currently receiving active anti-cancer therapy, or planned to start within 14 days, with intravenous cytotoxic chemotherapy (oral or intravenous), intravenous chemoimmunotherapy combination, immunotherapy alone, an oral CDK 4/6 inhibitor. (This does not apply to recipients of stem cell transplant and CAR T therapy) * Therapy may be neo/adjuvant or for metastatic disease * Eastern Cooperation Oncology Group (ECOG) Performance status (PS) of 0-2 Exclusion Criteria: \* Life expectancy of \< 12 months
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- The University of Kansas Cancer Center, Westwood CampusKansas City, Kansas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 4, 2023. Always confirm current availability with the study team.